Bayer : Bayer begins phase I study targeting GPC3 with actinium225 radiopharmaceutical in patients with advanced hepatocellular carcinoma
Bayer announced initiation of a phase I clinical trial with 225Ac─GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumours expressing Glypican─3 (GPC3) in patients with
Read full article »
Bayer is a Germany-based holding company that owns and operates businesses in areas such as pharmaceuticals, consumer health and crop protection across the globe.
Read more